AMDL Announces Launch of Antibiotic Levofloxacin in China
November 17 2006 - 5:00AM
PR Newswire (US)
TUSTIN, Calif., Nov. 17 /PRNewswire-FirstCall/ -- AMDL (AMEX:ADL)
announced today that its China subsidiary, Jade Pharmaceutical
Inc., has received approval from the China State Food and Drug
Administration (SFDA) for the antibiotic levofloxacin. Levofloxacin
is used to treat infections including pneumonia, urinary tract,
kidney and skin infection. It is in a class of antibiotics called
fluoroquinolones. Fluoroquinolones are the fastest growing
antibacterial class in terms of global revenue and are being used
increasingly to treat a broad range of infections. This market is
heavily dominated by ciprofloxacin and levofloxacin, which together
command 65 percent ($3.3 billion) of global sales. "China's
pharmaceutical market is undergoing tremendous growth and all signs
point to a continuation of this trend," said Gary Dreher, AMDL CEO.
Jade Pharmaceuticals will manufacture levofloxacin at the Jiangxi
Jade Biochemistry Ltd. manufacturing facility in the South China
City of Shargro in the Jiangxi Province of China. At present, this
product will only be sold in the People's Republic of China. About
AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California,
with operations in Shenzhen, Jaingxi and Jilin China through its
wholly owned subsidiary Jade Pharmaceutical Inc. is an
international biopharma company. AMDL together with Jade engages in
the development, manufacture and marketing of proprietary
pharmaceutical and testing products. More information about AMDL
and its additional products can be obtained at
http://www.amdl.com/. Forward-Looking Statements Statements in this
press release may constitute forward-looking statements and are
subject to numerous risks and uncertainties, including the failure
to complete successfully the development of new or enhanced
products, the Company's future capital needs, the lack of market
demand for any new or enhanced products the Company may develop,
any actions by the Company's partners that may be adverse to the
Company, the success of competitive products, other economic
factors affecting the Company and its markets, and other risks
detailed from time to time in the Company's filings with the
Securities and Exchange Commission. The actual results may differ
materially from those contained in this press release. The Company
disclaims any obligation to update any statements in this press
release. Contact: AMDL, Inc. Gary L. Dreher President & CEO
(714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher,
President & CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024